Kwok G - Search Results

1

Macrophage activation syndrome leading to fatality in subcutaneous panniculitis-like T cell lymphoma.

Kwok G, Loong F, Wong CS, Leung RY, Shek TW, Kwong YL. Kwok G, et al. Ann Hematol. 2014 May;93(5):873-5. doi: 10.1007/s00277-013-1888-9. Epub 2013 Aug 31. Ann Hematol. 2014. PMID: 23995578 No abstract available.

2

Pyrexia, massive hepatomegaly, and extreme hyperferritinemia.

Kwok G, Kan A, Leung RY, Tam S, Lau CS, Kwong YL. Kwok G, et al. Am J Med. 2014 Jun;127(6):e13-4. doi: 10.1016/j.amjmed.2014.01.015. Epub 2014 Mar 22. Am J Med. 2014. PMID: 24661971 No abstract available.

3

Pembrolizumab (Keytruda).

Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL. Kwok G, et al. Hum Vaccin Immunother. 2016 Nov;12(11):2777-2789. doi: 10.1080/21645515.2016.1199310. Epub 2016 Jul 11. Hum Vaccin Immunother. 2016. PMID: 27398650 Free PMC article. Review.

4

Sorafenib plus doxorubicin in advanced hepatocellular carcinoma patients: hope or hype?

Shing K, Kwok G, Chiu J, Cheung TT, Yau T. Shing K, et al. Among authors: kwok g. Ann Transl Med. 2020 Dec;8(24):1695. doi: 10.21037/atm-2020-130. Ann Transl Med. 2020. PMID: 33490207 Free PMC article. No abstract available.

5

Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.

Wong JSL, Kwok GGW, Tang V, Li BCW, Leung R, Chiu J, Ma KW, She WH, Tsang J, Lo CM, Cheung TT, Yau T. Wong JSL, et al. J Immunother Cancer. 2021 Feb;9(2):e001945. doi: 10.1136/jitc-2020-001945. J Immunother Cancer. 2021. PMID: 33563773 Free PMC article.

6

The Outcomes of Systemic Treatment in Recurrent Hepatocellular Carcinomas Following Liver Transplants.

Li BCW, Chiu J, Shing K, Kwok GGW, Tang V, Leung R, Ma KW, She WH, Tsang J, Chan A, Cheung TT, Lo CM, Yau T. Li BCW, et al. Adv Ther. 2021 Jul;38(7):3900-3910. doi: 10.1007/s12325-021-01800-z. Epub 2021 Jun 1. Adv Ther. 2021. PMID: 34061324

7

Neoadjuvant Therapy with Concurrent Docetaxel, Epirubicin, and Cyclophosphamide (TEC) in High-Risk HER2-Negative Breast Cancers.

Li B, Yau T, Leung R, Kwok G, Tsang J, Cheung P, Wong TT, Suen D, Kwong A, Chiu JW. Li B, et al. Among authors: kwok g. Adv Ther. 2021 Dec;38(12):5752-5762. doi: 10.1007/s12325-021-01933-1. Epub 2021 Oct 26. Adv Ther. 2021. PMID: 34699004

8

Thyroid Immune-Related Adverse Events in Patients with Cancer Treated with anti-PD1/anti-CTLA4 Immune Checkpoint Inhibitor Combination: Clinical Course and Outcomes.

Lui DTW, Lee CH, Tang V, Fong CHY, Lee ACH, Chiu JWY, Leung RCY, Kwok GGW, Li BCW, Cheung TT, Woo YC, Lam KSL, Yau T. Lui DTW, et al. Endocr Pract. 2021 Sep;27(9):886-893. doi: 10.1016/j.eprac.2021.01.017. Epub 2021 Feb 11. Endocr Pract. 2021. PMID: 33581327

9

Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC.

Dong Y, Wong JSL, Sugimura R, Lam KO, Li B, Kwok GGW, Leung R, Chiu JWY, Cheung TT, Yau T. Dong Y, et al. Cancers (Basel). 2021 Apr 18;13(8):1949. doi: 10.3390/cancers13081949. Cancers (Basel). 2021. PMID: 33919570 Free PMC article. Review.

10

A phase 1 study of pegylated recombinant arginase (PEG-BCT-100) in combination with systemic chemotherapy (capecitabine and oxaliplatin)[PACOX] in advanced hepatocellular carcinoma patients.

Yau T, Cheng PNM, Chiu J, Kwok GGW, Leung R, Liu AM, Cheung TT, Ng CT. Yau T, et al. Invest New Drugs. 2022 Apr;40(2):314-321. doi: 10.1007/s10637-021-01178-3. Epub 2021 Nov 4. Invest New Drugs. 2022. PMID: 34735674 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

59 results

Search Page

Filters